Johnson & Johnson OTHERNEUROSCIENCE — Percent Change (as a percent) increased by 47.5% to -19.2% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 73.8%, from -73.2% to -19.2%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates segment growth and momentum, whereas a negative percentage signals a contraction in demand or market share for these specific products.
This metric measures the period-over-period percentage growth or decline in net sales for the company's secondary neuros...
Comparable to segment-level revenue growth rates reported by peers in the pharmaceutical and biotechnology sectors, used to benchmark relative performance against industry trends.
jnj_segment_other_neuroscience_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -11.1% | 49.8% | 34.9% | 0% | 13.1% | -25.2% | 37.4% | -23.6% | -38.4% | -65.1% | -83.2% | -73.2% | -83.6% | -36.6% | -19.2% |
| QoQ Change | — | +548.6% | -29.9% | -100.0% | — | -292.4% | +248.4% | -163.1% | -62.7% | -69.5% | -27.8% | +12.0% | -14.2% | +56.2% | +47.5% |
| YoY Change | — | — | — | — | +218.0% | -150.6% | +7.2% | -280.2% | -52.4% | — | -252.5% | -90.6% | -28.4% | +56.0% | +73.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.